Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84

Bone

Volumn 42, Issue 6, 2008, Pages 1175-1183

  Miller, M A ^a   Bare, S P ^b   Recker, R R ^b   Smith, S Y ^c   Fox, J ^a  

^a NPS Pharmaceuticals   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Intratrabecular tunneling; Osteoporosis treatment; Ovariectomized rhesus monkey; Parathyroid hormone 1 84; Trabecular number

Indexed keywords

PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW BIOPSY; BONE STRUCTURE; BONE TURNOVER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; FEMUR; ILIAC CREST; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; RADIUS; RHESUS MONKEY; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE REMODELING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACACA MULATTA; OSTEOGENESIS; OVARIECTOMY; PARATHYROID HORMONE;

EID: 43149088008     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.01.029     Document Type: Article

References (22)

1. Mosekilde L., Søgaard C.H., Danielsen C.C., and Tørring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129 (1991) 421-428
2. Kimmel D.B., Bozzato R.P., Kronis K.A., Coble T., Sindrey D., Kwong P., et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132 (1993) 1577-1584
3. Stewart A.F., Cain R.L., Burr D.B., Jacob D., Turner C.H., and Hock J.M. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15 (2000) 1517-1525
4. 2 on bone formation and mechanical strength in ovariectomized rats. Calcif Tissue Int 68 (2001) 95-101
5. Fox J., Miller M.A., Newman M.K., Metcalfe A.F., Turner C.H., Recker R.R., et al. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79 (2006) 262-272
6. Jerome C.P., Burr D.B., Van Bibber T., Hock J.M., and Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fasicularis). Bone 28 (2001) 150-159
7. Horwitz M.J., Tedesco M.B., Gundberg C., Garcia-Ocana A., and Stewart A.F. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88 (2003) 569-575
8. Hodsman A., Bone H., Gallagher C., Kendler D., Brown J.P., Greenspan S., et al. Ostabolin-C™ increases lumbar spine BMD after 1 year of therapy: results of a phase II clinical trial. J Bone Miner Res 22 Suppl 1 (2007) S38
9. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
10. Greenspan S.L., Bone H.G., Ettinger M.P., Hanley D.A., Lindsay R., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 146 (2007) 326-339
11. Fox J, Newman MK, Turner CH, Guldberg RE, Smith SY. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif Tissue Int (in press). doi:10.1007/s00223-008-9108-7.
12. Fox J., Miller M.A., Newman M.K., Turner C.H., Recker R.R., and Smith S.Y. Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1-84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22 (2007) 260-273
13. Fox J., Miller M.A., Recker R.R., Turner C.H., and Smith S.Y. Effects of treatment of ovariectomized adult rhesus monkeys with parathyroid hormone 1-84 for 16 months on trabecular and cortical bone at the proximal femur. Calcif Tissue Int 81 (2007) 53-63
14. Iida-Klein A., Lu S.S., Cosman F., Lindsay R., and Dempster D.W. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. Bone 40 (2007) 391-398
15. Aaron J.E., de Vernejoul M.C., and Kanis J.A. Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis. Bone Miner 17 (1992) 399-413
16. Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. http://www.fda.gov/cder/guidance/osteo.pdf, 1994.
17. Fox J., Smith S.Y., and Wells D.S. Pharmacokinetics and pharmacodynamics of human parathyroid hormone 1-84 in adult ovariectomized rhesus monkeys. J Bone Miner Res 22 suppl 1 (2007) S439
18. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2 (1987) 595-610
19. Littell R.C., Stroup W.W., and Freund R.J. SAS for Linear Models. 4th edition (2002), SAS Press 256-261
20. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13 (1998) 1775-1782
21. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13 (2002) 97-104
22. Fox J., Miller M.A., Recker R.R., Bare S.P., Smith S.Y., and Moreau I. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5 (2005) 356-357